文献速递妇科

BRCA1/BRCA2双杂合突变上皮性卵巢癌的临床病理特征

Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
PubMed 文献 · Gynecol Oncol · 2019-11-18

该系统综述与病例分析汇总36例携带胚系BRCA1/2双突变的EOC患者,并与COEUR队列中已知BRCA状态的EOC患者比较。双突变患者诊断中位年龄51.9岁,82%为晚期,5年生存率60%,显著低于BRCA2突变携带者76%,但与BRCA1突变携带者51%无显著差异。

要点

  • BRCA1/2双突变EOC患者诊断中位年龄51.9岁,82%诊断时已为III-IV期。
  • 双突变患者5年生存率60%,显著低于BRCA2突变携带者76%(p=.03)。
  • 双突变患者5年生存率与BRCA1突变携带者51%相比无显著差异(p=.37)。

核心结论

  • 数据提示两种突变可能存在某种共显性效应,但患者结局更接近BRCA1突变携带者,伴不良预后因素。

研究设计与样本

  • 系统综述英语文献并检索三个报告EOC患者携带BRCA1/2双突变的数据库,共纳入36例携带胚系BRCA1/2双突变的EOC患者。
  • 对照为COEUR队列中已知胚系BRCA1/BRCA2突变状态的高级别浆液性EOC女性:非携带者376例、BRCA1突变携带者65例、BRCA2突变携带者38例。

主要发现

  • BRCA1/2双突变患者诊断中位年龄51.9岁,与BRCA1突变携带者49.7岁相似(p=.58),低于BRCA2突变携带者58.1岁(p=.02)。
  • 多数双突变患者诊断时为晚期(III-IV期占82%),且为奠基者/常见突变携带者(69%)。
  • 组织免疫染色显示孕激素受体无表达及上皮内炎症水平低。
  • 双突变患者5年生存率60%,显著低于BRCA2突变携带者76%(p=.03),但与BRCA1突变携带者51%相比无显著差异(p=.37)。

关键数值与推荐

  • BRCA1/2双突变患者诊断中位年龄51.9岁。
  • BRCA1/2双突变患者III-IV期占82%,奠基者/常见突变占69%。
  • BRCA1/2双突变患者5年生存率60%,BRCA2突变携带者76%(p=.03),BRCA1突变携带者51%(p=.37)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carriers of pathogenic variants in both BRCA1 and BRCA2 genes as a double mutation (BRCA1/2 DM) have been rarely reported in women with epithelial ovarian cancer (EOC). METHODS: We reviewed the English literature and interrogated three repositories reporting EOC patients carrying BRCA1/2 DM. The clinicopathological parameters of 36 EOC patients carrying germline BRCA1/2 DM were compared to high-grade serous EOC women of the COEUR cohort with known germline BRCA1/BRCA2 mutation carrier status (n = 376 non-carriers, n = 65 BRCA1 and n = 38 BRCA2). Clinicopathological parameters evaluated were age at diagnosis, stage of disease, loss of heterozygosity, type of mutation, immunohistochemistry profile, progression occurrence and survival. RESULTS: Median age at diagnosis of BRCA1/2 DM patients was 51.9 years, similar to BRCA1 mutation carriers (49.7 years, p = .58) and younger than BRCA2 mutation carriers (58.1 years, p = .02). Most patients were diagnosed at advanced stage (III-IV; 82%) and were carriers of founder/frequent mutations (69%). Tissue immunostainings revealed no progesterone receptor expression and low intraepithelial inflammation. The 5-year survival rate (60%) was significantly lower than that of BRCA2 mutation carriers (76%, p = .03) but not of BRCA1 mutation carriers (51%, p = .37). CONCLUSIONS: Our data suggests some co-dominant effect of both mutations but the outcome of these patients more closely resembled that of BRCA1 mutation carriers with poor prognosis factors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Le Page C, Rahimi K, Rodrigues M, et al. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecol Oncol. 2019. PMID: 31753525. doi:10.1016/j.ygyno.2019.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。